Definium Therapeutics Finalizes Upsized $805M Public Offering at $34.00/Share

summarizeSummary

Definium Therapeutics finalized an upsized public offering, raising approximately $805 million by selling common shares at $34.00 each, including the full exercise of the underwriters' option, to fund R&D and commercialization efforts.

check_boxKey Events

• Underwriting Agreement Finalized

  Definium Therapeutics entered into an underwriting agreement on June 23, 2026, for a public offering of common shares.

• Upsized Public Offering Priced

  The company priced an upsized offering of 20,588,236 common shares at $34.00 per share. This follows a preliminary announcement of a $500 million offering and a subsequent pricing of a $700 million offering.

• Underwriters' Option Fully Exercised

  The underwriters fully exercised their option to purchase an additional 3,088,235 common shares on June 24, 2026, bringing the total shares sold to 23,676,471.

• Significant Capital Raised

  The offering is expected to generate approximately $805 million in gross proceeds and $758 million in net proceeds for the company.

auto_awesomeAnalysis

Definium Therapeutics has finalized an upsized public offering, raising approximately $805 million in gross proceeds by selling 23,676,471 common shares at $34.00 per share. This includes the full exercise of the underwriters' option to purchase additional shares. While the offering price represents a significant discount of nearly 20% to the current market price, this substantial capital infusion is critical for funding the research and development of product candidates, particularly for the preparation of potential commercialization of DT120 ODT, following recent positive Phase 3 results. The funds also provide essential working capital and general corporate purposes, extending the company's financial runway.